BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Epizyme (EPZM) Appoints Jason P. Rhodes President


7/3/2013 6:51:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 3, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason P. Rhodes, Executive Vice President and Chief Financial Officer, has been named President of Epizyme. Mr. Rhodes, who was previously Executive Vice President and Chief Financial Officer, will continue to be Chief Financial Officer and report to Robert J. Gould, Ph.D., Chief Executive Officer.

"Jason joined Epizyme in March 2010 and has been instrumental in our growth and success," said Dr. Gould. "He has served as Chief Business Officer and Chief Financial Officer during his tenure and has been a key partner for me in building the business and charting our strategic course. I am pleased to recognize his many contributions with this promotion. I look forward to Jason's continued growth and leadership as part of our executive team at Epizyme."

Prior to joining Epizyme, from July 2007 to March 2010, Mr. Rhodes served as Vice President, Business Development at Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) where he drove the establishment and management of several key strategic alliances and contributed to the growth of the business in many ways. Prior to Alnylam, he was a founder and partner with Fidelity Biosciences, Fidelity Investments' biopharma venture capital group. Mr. Rhodes received a B.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania.

"On behalf of the Board of Directors, I congratulate Jason on his appointment as President," said David Mott, Lead Independent Director of Epizyme. "The strong partnership between Robert and Jason has helped the impressive leadership team and Epizyme as an organization build a unique company with world class science, outstanding business execution, and an innovative and dynamic strategy. Most importantly, we believe that we are on the cusp of translating our success to date into a family of important new therapeutics for patients with genetically defined cancers. We look forward to Jason's continued contributions to our growth and success and to improving the lives of cancer patients and their families."

"I am grateful for this recognition and honored to be a part of the strong leadership team at Epizyme," said Epizyme's new President, Jason P. Rhodes. "I look forward to continuing to collaborate with Robert and the entire Epizyme team to build value for shareholders and to deliver innovative new therapeutics to cancer patients."

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Epizyme
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES